Formulation, In Vitro And In Vivo Evaluation Of Repaglinide Pulsatile Release Delivery System For The Treatment Of Daibetus Melitus

S. Vasanth Kumar, K. Senthilkumaran — Thu, 04 Jul 2024 00:00:00 +0000

In present study aimed to optimise the pulsatile release tablet of repaglinide, the Box-Behnken design paradigm was used. 16.14 mg of CCS, 28.91 mg of lactose, and 4.37 mg of eudragit were found to be the appropriate formulation variables, and the tablet's response was 94.45%. medication released, followed by a 5.99-hour lag time (T) and a desirability of around 1. FT-IR analysis revealed significant peaks of REP was found in tablets, indicates no interaction between drug and polymers. Assay of REP formulation showed 98.89±0.5 % REP was present in the chronomodualted tablet and bioavailability of REP was found to be 103.77 %. A chronomodualted drug delivery of REP for the treatment of diabetes mellitus (The dawn phenomenon leads to high levels of blood sugar, a condition called hyperglycemia. It usually happens between 4 a.m. and 8 a.m) was successfully developed. The system was found satisfactory in term of drug release after lag time of 6 hrs. The dosage form can be taken at bad time and release the drug at early morning when high level of blood glucose reached in blood. The chronomodulated delivery system could release the drug repaglinide at early morning and control the blood sugar level and its leads to patience compliance.

Journal of Pharmacreations

Formulation, In Vitro And In Vivo Evaluation Of Repaglinide Pulsatile Release Delivery System For The Treatment Of Daibetus Melitus